







The latest findings of the RECOVER study are expected to help standardize the definition of long covid and influence how the condition is diagnosed and studied.
Long Covid Studies - Possible long COVID treatments
See all researched treatments for long COVID, along with evidence summaries.
Long COVID finally gets a universal definition
If broadly adopted, this inclusive description of long COVID will help legitimize the ongoing struggles millions of people are facing post-infection.

Long COVID stemmed from mild cases of COVID-19 in most people
90% of people living with long COVID initially experienced only mild illness.

Long COVID could be a ticking time bomb
Long COVID isn't novel: other viruses in history have had similar “long” arcs — with devastating repercussions

Long COVID still has no cure — so these patients are turning to research
With key long COVID trials yet to yield results, people with the condition are trying to change how clinical trials are done.

Long-COVID recovery varies sharply by symptoms, study finds
Fewer than one in five people with multiple body systems impacted experience sustained improvement within three years of infection, a study found.

Timing of Long COVID Improvement in Prospectively Followed RECOVER-Adult Participants
Background: Long COVID (LC) is widespread; however, limited information has been reported on the likelihood that symptoms remit over time. Objective: To evaluate the likelihood of improvement among persons with likely LC. Design: Prospective, multisite cohort study (RECOVER-Adult [Researching COVID to Enhance Recovery]). Setting: 83 U.S.-based sites across 33 states; Washington, DC; and Puerto Rico. Participants: 1019 persons in RECOVER-Adult with likely LC (LC Research Index [LCRI] ≥11) 12 months after first SARS-CoV-2 infection. Measurements: The primary outcome was time until 2 consecutive study visits with LCRI less than 11. Secondary outcomes were time until LCRI measure reduced 50% or more and quality of life was good or better, and LCRI decreased to 0. Unadjusted estimates of cumulative incidence and adjusted marginal cumulative incidence by age, sex, SARS-CoV-2 wave, and LC subtype were reported across all follow-up time points. Results: An estimated 36.2% (95% CI, 33.0% to 39.5%) met the primary outcome by 24 months after infection, and 50.1% (CI, 46.1% to 54.0%) met the primary outcome by 36 months. An estimated 56.4% (CI, 52.2% to 60.4%) and 26.9% (CI, 23.3% to 30.5%), respectively, met the 2 secondary outcomes by 36 months. Among persons who still reported likely LC at 18 months and 24 months after first infection, relative timing of subsequent symptom improvement was similar. Limitation: Findings in this observational cohort are interpretable in a population with prevalent likely LC and do not address causal relationships between individual characteristics and symptom improvement. Conclusion: Among persons with likely LC 12 months after initial SARS-CoV-2 infection, one half experience meaningful reductions in symptoms by 36 months, whereas a quarter experience complete remission of symptoms. These findings underscore both the potential for natural recovery and the urgent need for placebo-controlled therapeutic intervention trials. Primary Funding Source: National Institutes of Health.

Timing of Long COVID Improvement in Prospectively Followed RECOVER-Adult Participants
Background: Long COVID (LC) is widespread; however, limited information has been reported on the likelihood that symptoms remit over time. Objective: To evaluate the likelihood of improvement among persons with likely LC. Design: Prospective, multisite cohort study (RECOVER-Adult [Researching COVID to Enhance Recovery]). Setting: 83 U.S.-based sites across 33 states; Washington, DC; and Puerto Rico. Participants: 1019 persons in RECOVER-Adult with likely LC (LC Research Index [LCRI] ≥11) 12 months after first SARS-CoV-2 infection. Measurements: The primary outcome was time until 2 consecutive study visits with LCRI less than 11. Secondary outcomes were time until LCRI measure reduced 50% or more and quality of life was good or better, and LCRI decreased to 0. Unadjusted estimates of cumulative incidence and adjusted marginal cumulative incidence by age, sex, SARS-CoV-2 wave, and LC subtype were reported across all follow-up time points. Results: An estimated 36.2% (95% CI, 33.0% to 39.5%) met the primary outcome by 24 months after infection, and 50.1% (CI, 46.1% to 54.0%) met the primary outcome by 36 months. An estimated 56.4% (CI, 52.2% to 60.4%) and 26.9% (CI, 23.3% to 30.5%), respectively, met the 2 secondary outcomes by 36 months. Among persons who still reported likely LC at 18 months and 24 months after first infection, relative timing of subsequent symptom improvement was similar. Limitation: Findings in this observational cohort are interpretable in a population with prevalent likely LC and do not address causal relationships between individual characteristics and symptom improvement. Conclusion: Among persons with likely LC 12 months after initial SARS-CoV-2 infection, one half experience meaningful reductions in symptoms by 36 months, whereas a quarter experience complete remission of symptoms. These findings underscore both the potential for natural recovery and the urgent need for placebo-controlled therapeutic intervention trials. Primary Funding Source: National Institutes of Health.

Researchers identify link in pathology between long COVID and chronic fatigue syndrome
Researchers knew there were similarities in the symptoms. Now they've found an overlap in the pathology of the two illnesses.
What we now know about long COVID and our brains
After three years of the COVID-19 pandemic we know more about PCNS or Long COVID, but there’s a vital need for more research says University of Melbourne expert

Current status and future perspectives on the mechanistic and pathophysiological understanding of long COVID
Viral and infectious illnesses can exert profound and enduring effects on population health and well-being. In the aftermath of SARS-CoV-2 infection, post-acute sequelae, collectively referred to as Long COVID, have emerged as a major global health challenge, affecting more than 400 million people and contributing to estimated annual economic costs exceeding $1 trillion. Long COVID encompasses a wide and heterogeneous spectrum of debilitating symptoms, including cognitive dysfunction, sleep disturbances, severe fatigue, and post-exertional malaise. Despite its substantial burden, fundamental uncertainties remain regarding its underlying pathophysiology, the development of robust diagnostic criteria, and the identification of effective therapeutic options. This review synthesises current evidence on the biological mechanisms thought to contribute to Long COVID, spanning immune dysregulation, viral persistence, autonomic dysfunction, microvascular pathology, and other emerging hypotheses. We examine advances and limitations in contemporary diagnostic approaches and critically appraise existing treatment strategies, highlighting inconsistencies and gaps that hinder clinical consensus. By integrating interdisciplinary insights, this review underscores the urgent need for mechanistic clarity, validated diagnostic frameworks, and rigorously evaluated treatment pathways. Addressing these gaps will be essential to developing effective, evidence-based management strategies and mitigating the long-term impact of Long COVID on global health.

Current status and future perspectives on the mechanistic and pathophysiological understanding of long COVID
Viral and infectious illnesses can exert profound and enduring effects on population health and well-being. In the aftermath of SARS-CoV-2 infection, post-acute sequelae, collectively referred to as Long COVID, have emerged as a major global health challenge, affecting more than 400 million people and contributing to estimated annual economic costs exceeding $1 trillion. Long COVID encompasses a wide and heterogeneous spectrum of debilitating symptoms, including cognitive dysfunction, sleep disturbances, severe fatigue, and post-exertional malaise. Despite its substantial burden, fundamental uncertainties remain regarding its underlying pathophysiology, the development of robust diagnostic criteria, and the identification of effective therapeutic options. This review synthesises current evidence on the biological mechanisms thought to contribute to Long COVID, spanning immune dysregulation, viral persistence, autonomic dysfunction, microvascular pathology, and other emerging hypotheses. We examine advances and limitations in contemporary diagnostic approaches and critically appraise existing treatment strategies, highlighting inconsistencies and gaps that hinder clinical consensus. By integrating interdisciplinary insights, this review underscores the urgent need for mechanistic clarity, validated diagnostic frameworks, and rigorously evaluated treatment pathways. Addressing these gaps will be essential to developing effective, evidence-based management strategies and mitigating the long-term impact of Long COVID on global health.

People With Multisystem Long Covid See Lower Recovery, Research Finds
People whose long Covid affects multiple body systems are far less likely to improve than overall recovery estimates suggest, with fewer than one in five experiencing sustained improvement within three years of infection, according to a US study.

I Don't Know Anyone With Long Covid
Yes. You do. It might even be you. Let's take a look at why people don't realize, or can't admit, that they're dealing with Long Covid.

New research shows younger and middle-aged adults have worse long COVID symptoms than older adults
New study from Northwestern Medicine finds symptoms occurred regardless of mild or severe COVID-19 infection

What Are COVID-19’s Long-Term Medical Effects?
Fascinating email from TPM Reader JO, whose personal bio is tailor-made for...
